Guardant Health Inc (NASDAQ: GH) has experienced a decline in its stock price by -8.59 compared to its previous closing price of 26.79. However, the company has seen a gain of 3.03% in its stock price over the last five trading days. businesswire.com reported 2024-09-13 that PALO ALTO, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from several studies utilizing Guardant technology to advance precision oncology at the European Society for Medical Oncology Congress (ESMO) in Barcelona, Spain, Sept. 13-17, 2024. Data on the Guardant Reveal™ minimal residual disease test in locally advanced rectal cancer patients enrolled in the NO-CUT trial.
Is It Worth Investing in Guardant Health Inc (NASDAQ: GH) Right Now?
The 36-month beta value for GH is also noteworthy at 1.11. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for GH is 116.91M, and at present, short sellers hold a 9.51% of that float. The average trading volume of GH on September 16, 2024 was 2.11M shares.
GH’s Market Performance
The stock of Guardant Health Inc (GH) has seen a 3.03% increase in the past week, with a -14.19% drop in the past month, and a -18.93% fall in the past quarter. The volatility ratio for the week is 5.61%, and the volatility levels for the past 30 days are at 4.57% for GH. The simple moving average for the past 20 days is -6.45% for GH’s stock, with a -0.93% simple moving average for the past 200 days.
Analysts’ Opinion of GH
Many brokerage firms have already submitted their reports for GH stocks, with Guggenheim repeating the rating for GH by listing it as a “Buy.” The predicted price for GH in the upcoming period, according to Guggenheim is $36 based on the research report published on June 28, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see GH reach a price target of $32. The rating they have provided for GH stocks is “Buy” according to the report published on June 03rd, 2024.
Craig Hallum gave a rating of “Buy” to GH, setting the target price at $28 in the report published on April 24th of the current year.
GH Trading at -16.30% from the 50-Day Moving Average
After a stumble in the market that brought GH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.88% of loss for the given period.
Volatility was left at 4.57%, however, over the last 30 days, the volatility rate increased by 5.61%, as shares sank -13.99% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.38% lower at present.
During the last 5 trading sessions, GH rose by +1.14%, which changed the moving average for the period of 200-days by -1.48% in comparison to the 20-day moving average, which settled at $25.98. In addition, Guardant Health Inc saw -9.46% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GH starting from Joyce Meghan V., who sale 100 shares at the price of $27.87 back on Jun 04 ’24. After this action, Joyce Meghan V. now owns 4,621 shares of Guardant Health Inc, valued at $2,787 using the latest closing price.
Kalia Kumud, the Chief Information Officer of Guardant Health Inc, purchase 2,187 shares at $17.82 during a trade that took place back on Mar 18 ’24, which means that Kalia Kumud is holding 12,722 shares at $38,963 based on the most recent closing price.
Stock Fundamentals for GH
Current profitability levels for the company are sitting at:
- -0.79 for the present operating margin
- 0.82 for the gross margin
The net margin for Guardant Health Inc stands at -0.76. The total capital return value is set at -0.36. Equity return is now at value -337.16, with -28.46 for asset returns.
Based on Guardant Health Inc (GH), the company’s capital structure generated 1.0 points at debt to capital in total, while cash flow to debt ratio is standing at -0.24. The debt to equity ratio resting at -724.69. The interest coverage ratio of the stock is 198.43.
Currently, EBITDA for the company is -519.63 million with net debt to EBITDA at -0.61. When we switch over and look at the enterprise to sales, we see a ratio of 5.18. The receivables turnover for the company is 6.4for trailing twelve months and the total asset turnover is 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.40.
Conclusion
In summary, Guardant Health Inc (GH) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
